Truist Securities Reiterates Immunovant (IMVT) at Buy, sees IMVT-1402 data as "best in class profile"
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $30.00 price target on Immunovant (NASDAQ: IMVT) following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
